We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electric Sensor Detects DNA for Disease Diagnosis

By LabMedica International staff writers
Posted on 01 Sep 2009
A newly developed electrical DNA biosensor will help to characterize pathogens and measure mRNA levels during expression profiling. More...
It will be suitable for point-of-care (POC) diagnosis and criminal investigations.

Scientists in Singapore developed the new electronic sensor that will offer a faster, less expensive, and more practical alternative to tests now used to detect DNA. The new lab-on-a-chip test will lead to wider, more convenient use of DNA testing.

Zhiqiang Gao, Ph.D., at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) and colleagues developed a nanogap sensor. They used a pair of micro-sized metal electrodes separated by a nanogap, 1/50,000 the width of a human hair, in combination with special chemical probes to capture tiny segments of DNA. The newly formed circuit then translated the presence of DNA into an electrical signal that that was measured by a computer. In laboratory tests, the sensor showed excellent sensitivity at detecting trace amounts of human DNA.

Another feature of the biosensor was its ability to capture DNA strands more effectively. The two surfaces of the sensor were coated with a chemically treated capture probe solution through an electrochemical technique specially developed by IBN. This allowed DNA strands to stick more easily to the sensor, resulting in a faster and more accurate analysis.

Current methods for detecting DNA use the polymerase chain reaction (PCR), which amplifies trace amounts of DNA, making it easier to detect the genetic material. The amplification step is one of the reasons why PCR tests can be expensive, cumbersome, and imprecise. The newly developed biosensor should eliminate the need for DNA amplification altogether.

"This new biosensor holds significant promise to speed up on-going efforts in the detection and diagnosis of debilitating diseases such as cancer, cardiovascular problems, and infectious viruses. We aim to make healthcare accessible to the masses with early disease diagnosis as the critical driving force behind the research we undertake here at IBN," said Jackie Y. Ying, Ph.D., executive director of IBN.

The study was published in the September 2, 2009, issue of the Journal of the American Chemical Society.

Related Links:

Institute of Bioengineering and Nanotechnology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.